Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04825704
Other study ID # BupivacTons20
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date October 27, 2021
Est. completion date June 27, 2023

Study information

Verified date August 2023
Source Nordlandssykehuset HF
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A placebo-controlled and double-blind study is planned according to current legislation and ICH GCP guidelines with 80 patients at Nordland Hospital, Bodø. Fifty percent are randomized to receive bupivacaine 5 mg / ml on the gauze swabs used to stop the bleeding after tonsillectomy, and 50% receive 0.9% sodium chloride. Pain at rest and pain when swallowing according to numerical rating scale (0-10), as well as the presence of the following symptoms (yes / no): nausea, vomiting, food intake, bleeding, fever, need for extra painkillers in the form of morphine or similar will be registered 1, 2, 3, 4, 5, 6 hours and 1, 2 4 and 6 days after the operation. Differences are analyzed with "mixed models" statistics and the results will be published in a peer-based journal.


Recruitment information / eligibility

Status Completed
Enrollment 84
Est. completion date June 27, 2023
Est. primary completion date June 27, 2023
Accepts healthy volunteers No
Gender All
Age group 5 Years to 40 Years
Eligibility Inclusion Criteria: All patients undergoing isolated tonsillectomy from the age of 5 years to 40 years Exclusion Criteria: 1. Known allergy to local anesthetics. 2. Patients using painkillers in the form of opioids fixed before inclusion in the study. People who have a lot of pain often have more pain after known painful stimuli, such as surgery. This is known as the phenomenon of "central sensitization" and "opioid-induced hyperalgesia" and will probably contribute to great heterogeneity within the groups. Because very few people use opioids regularly from those who have an isolated tonsillectomy performed, it can make it difficult to detect any differences between the groups, and the number is far too low to be able to perform stratified analyzes on only these people. 3. Persons weighing less than 10 kg. 4. Persons over the age of 18 who are not competent to give consent. 5. Patients using class Ib antiarrhythmics (lidocaine, mexiletine) due to increased risk of additive toxicity due to structural similarities. (see SPC) 6. Known partial or total heart block that has not had a pacemaker inserted (see SPC) 7. Severe hepatic failure (spontaneous prothrombin time -international normalized ratio (PT-INR)> 2.0). These patients are not offered this type of procedure as day surgery due to the high risk of complications for the surgery itself. 8. Severe renal failure (estimated glomerular filtration rate <15 ml / min / 1.73m2).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Bupivacaine
Topical administration of bupivacaine via gauze swab in the tonsillar fossae after removal of throat tonsils.
Sodium chloride
Topical administration of 0,9% sodium chloride via gauze swab in the tonsillar fossae after removal of throat tonsils.

Locations

Country Name City State
Norway Nordland Hospital Bodø

Sponsors (1)

Lead Sponsor Collaborator
Nordlandssykehuset HF

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary Difference in self-reported pain at rest. Difference in self-reported pain at rest by the numerical rating scale (0-10, 0 = no pain, 10 worst pain) for patients aged 10 years and older, and indicated by the faces pain scale-revised (0-10, 0 = no pain, 10 worst pain) for patients aged 5-10 years old, on average over all measurement times. Pain is registered at 1,2,3,4,5 and 6 hours. Until 6 hours postoperatively.
Secondary Difference in pain when swallowing on average over all measurement times. Difference in pain according to the numerical rating scale (0-10, 0 = no pain, 10 worst pain) between the two groups when swallowing on average over all measurement times. Pain is registered at 1,2,3,4,5 and 6 hours, and 1,2,4 and 6 days postoperatively. Until 6 days postoperatively
Secondary Graphic Descriptive representation of numerical rating scale (0-10, 0 = no pain, 10 worst pain) in a curve diagram Pain is registered at 1,2,3,4,5 and 6 hours, and 1,2,4 and 6 days postoperatively Until 6 days postoperatively
Secondary Difference in numerical rating scale (0-10, 0 = no pain, 10 worst pain) at rest between the groups day 1 after the operation Until 1 day postoperatively
Secondary Difference in numerical rating scale (0-10, 0 = no pain, 10 worst pain) at rest between the groups day 6 after the operation Until 6 days postoperatively
Secondary Difference in numerical rating scale (0-10, 0 = no pain, 10 worst pain) when swallowing between the groups day 1 after the operation Until 1 day postoperatively
Secondary Difference in numerical rating scale (0-10, 0 = no pain, 10 worst pain) when swallowing between the groups day 6 after the operation Until 6 days postoperatively
Secondary Difference in defined daily doses of morphine in the two groups Until 6 days postoperatively
Secondary Difference in number and type a) serious adverse event, b) serious adverse reaction and c) adverse reaction where the adverse reaction is an adverse medical event where there is a probable or possible association with the test preparation Until one hour postoperatively
Secondary Difference in hours of nausea Until 6 days postoperatively
Secondary Difference in the number of times eaten solid food Until 6 days postoperatively
Secondary Number of vomiting episodes Until 6 days postoperatively
Secondary Number of episodes in which blood is spit for more than 30 minutes from 1 hour postoperatively Until 6 days postoperatively
Secondary Hours with measured fever> = 38 C rectally, tympanometric or with temporal scanner Until 6 days postoperatively
See also
  Status Clinical Trial Phase
Completed NCT05480111 - The Role of Quadratus Lumborum Blocks Following Minimally Invasive Hysterectomy Phase 4
Completed NCT06129305 - Erector Spina Muscle Distance From the Skin at Different Thoracal Elevations
Completed NCT04401826 - Micro-surgical Treatment of Gummy Smile N/A
Recruiting NCT04020133 - the Role of Popliteal Plexus Block in Pain Management After Anterior Cruciate Ligament Reconstruction. N/A
Completed NCT03023462 - Efficacy of an Anterior Quadratus Lumborum Block vs. a TAP-block for Inguinal Hernia Repair N/A
Completed NCT03546738 - Spinal Cord Burst Stimulation for Chronic Radicular Pain Following Lumbar Spine Surgery N/A
Completed NCT03652103 - Efficiency of Erector Spinae Plane Block For Patients Undergoing Percutaneous Nephrolithotomy Phase 4
Withdrawn NCT03528343 - Narcotic vs. Non-narcotic Pain Regimens After Pediatric Appendectomy Phase 1/Phase 2
Terminated NCT03261193 - ITM + Bupivacaine QLB vs. ITM + Sham Saline QLB for Cesarean Delivery Pain Phase 3
Completed NCT02525133 - Phase 3 Study of Efficacy and Safety of the XaraColl® Bupivacaine Implant After Hernioplasty Phase 3
Completed NCT03244540 - Regional Analgesia After Cesarean Section Phase 4
Enrolling by invitation NCT05316168 - Post Operative Pain Management for ACL Reconstruction Phase 3
Recruiting NCT04130464 - Intraperitoneal Infusion of Analgesic for Postoperative Pain Management Phase 4
Enrolling by invitation NCT04574791 - Addition of Muscle Relaxants in a Multimodal Analgesic Regimen for Analgesia After Primary Total Knee Arthroplasty N/A
Completed NCT04073069 - Scalp Infiltration With Diprospan Plus Ropivacaine for Postoperative Pain After Craniotomy in Adults Phase 4
Completed NCT04526236 - Influence of Aging on Perioperative Methadone Dosing Phase 4
Recruiting NCT05351229 - Intrathecal Morphine for Analgesia in Video-assisted Thoracic Surgery Phase 4
Enrolling by invitation NCT05543109 - Ultrasound Guided Psoas Compartment Block vs Suprainguinal Fascia Iliaca Compartment Block N/A
Completed NCT05346588 - THRIVE Feasibility Trial Phase 3
Completed NCT04919317 - Combination Dexamethasone and Bupivacaine Pain Control in Reduction Mammaplasty Phase 2